Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review-Reference-Cited by-同舟云学术

Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

Published:2013-04-01 Issue:2 Volume:20 Page:121-124
ISSN:1718-7729
Container-title:Current Oncology
language:en
Short-container-title:Current Oncology

Author:

Hoch J.S.,Sabharwal M.

Abstract

JSH: In July 2011, the pan-Canadian Oncology Drug Review [pcodr (http://www.pcodr.ca/)] began accepting submissions by pharmaceutical manufacturers and clinician-based tumour groups to have cancer drugs reimbursed by provincial payers in Canada. Doesn’t Canada already have a body reviewing drugs? [...]

Publisher

MDPI AG

Link

https://www.mdpi.com/1718-7729/20/2/1315/pdf

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is it the Patient or is it the Disease – Considerations when Applying Different Cost Effectiveness Thresholds in Making Reimbursement Decisions;2023-08-03

2. Analyzing a Cost-Effectiveness Dataset: A Speech and Language Example for Clinicians;Seminars in Speech and Language;2022-06

3. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs;Current Oncology;2021-01-20

4. Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts;Value in Health;2020-04

5. Financial relationships between patient and consumer representatives and the health industry: A systematic review;Health Expectations;2020-04